Huntington National Bank’s Anika Therapeutics ANIK Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $13.7K | Hold |
944
| – | – | ﹤0.01% | 1773 |
|
|
2025
Q4 | $9.07K | Buy |
944
+135
| +17% | +$1.29K | ﹤0.01% | 1820 |
|
|
2025
Q3 | $7.61K | Buy |
809
+163
| +25% | +$1.56K | ﹤0.01% | 1903 |
|
|
2025
Q2 | $6.83K | Buy |
646
+645
| +64,500% | +$8.14K | ﹤0.01% | 1904 |
|
|
2025
Q1 | $15 | Sell |
1
-147
| -99% | -$2.44K | ﹤0.01% | 3593 |
|
|
2024
Q4 | $2.44K | Buy |
148
+147
| +14,700% | +$2.9K | ﹤0.01% | 2204 |
|
|
2024
Q3 | $25 | Hold |
1
| – | – | ﹤0.01% | 3372 |
|
|
2024
Q2 | $25 | Sell |
1
-200
| -100% | -$5.18K | ﹤0.01% | 3324 |
|
|
2024
Q1 | $5.11K | Hold |
201
| – | – | ﹤0.01% | 1912 |
|
|
2023
Q4 | $4.55K | Buy |
201
+200
| +20,000% | +$4.14K | ﹤0.01% | 1917 |
|
|
2023
Q3 | $19 | Hold |
1
| – | – | ﹤0.01% | 3190 |
|
|
2023
Q2 | $26 | Sell |
1
-101
| -99% | -$2.7K | ﹤0.01% | 3006 |
|
|
2023
Q1 | $2.93K | Hold |
102
| – | – | ﹤0.01% | 1869 |
|
|
2022
Q4 | $3.02K | Hold |
102
| – | – | ﹤0.01% | 1705 |
|
|
2022
Q3 | $2K | Hold |
102
| – | – | ﹤0.01% | 1834 |
|
|
2022
Q2 | $2K | Hold |
102
| – | – | ﹤0.01% | 1868 |
|
|
2022
Q1 | $3K | Hold |
102
| – | – | ﹤0.01% | 1823 |
|
|
2021
Q4 | $4K | Hold |
102
| – | – | ﹤0.01% | 1754 |
|
|
2021
Q3 | $4K | Hold |
102
| – | – | ﹤0.01% | 1581 |
|
|
2021
Q2 | $4K | Hold |
102
| – | – | ﹤0.01% | 1583 |
|
|
2021
Q1 | $4K | Hold |
102
| – | – | ﹤0.01% | 1473 |
|
|
2020
Q4 | $5K | Hold |
102
| – | – | ﹤0.01% | 1390 |
|
|
2020
Q3 | $4K | Hold |
102
| – | – | ﹤0.01% | 1346 |
|
|
2020
Q2 | $4K | Sell |
102
-13
| -11% | -$428 | ﹤0.01% | 1332 |
|
|
2020
Q1 | $3K | Hold |
115
| – | – | ﹤0.01% | 1385 |
|
|
2019
Q4 | $6K | Buy |
115
+18
| +19% | +$1.05K | ﹤0.01% | 1470 |
|
|
2019
Q3 | $5K | Hold |
97
| – | – | ﹤0.01% | 1362 |
|
|
2019
Q2 | $4K | Buy |
97
+1
| +1% | +$36 | ﹤0.01% | 1440 |
|
|
2019
Q1 | $3K | Sell |
96
-1
| -1% | -$34 | ﹤0.01% | 1442 |
|
|
2018
Q4 | $3K | Hold |
97
| – | – | ﹤0.01% | 1511 |
|
|
2018
Q3 | $4K | Buy |
97
+1
| +1% | +$40 | ﹤0.01% | 1524 |
|
|
2018
Q2 | $3K | Hold |
96
| – | – | ﹤0.01% | 1489 |
|
|
2018
Q1 | $5K | Hold |
96
| – | – | ﹤0.01% | 1419 |
|
|
2017
Q4 | $5K | Sell |
96
-10
| -9% | -$553 | ﹤0.01% | 1455 |
|
|
2017
Q3 | $6K | Buy |
106
+38
| +56% | +$1.99K | ﹤0.01% | 1425 |
|
|
2017
Q2 | $3K | Buy |
+68
| New | +$3.13K | ﹤0.01% | 1428 |
|
Other funds holding ANIK
CP
VCM
BFM
CM
Huntington National Bank's ANIK Position: Q1 2026 in Review
Huntington National Bank held its Anika Therapeutics (ANIK) position steady in Q1 2026 at 944 shares worth $13.7K. The position accounts for ﹤0.01% of the portfolio, ranked #1773.
Huntington National Bank first reported a position in ANIK in Q2 2017 and has held it in 36 quarters since. 130 funds tracked by Wall St. Rank hold ANIK as of Q1 2026.
- Huntington National Bank held 944 shares of Anika Therapeutics worth $13.7K as of Q1 2026.
- Huntington National Bank left its Anika Therapeutics share count unchanged in Q1 2026.
- Anika Therapeutics made up ﹤0.01% of Huntington National Bank's portfolio in Q1 2026, its #1773 holding.
- Huntington National Bank first reported a position in Anika Therapeutics in Q2 2017 and has held it in 36 quarters since.
- 130 funds tracked by Wall St. Rank held Anika Therapeutics as of Q1 2026.
Based on Huntington National Bank's 13F filing for Q1 2026, filed 15 May 2026.